배경 : BiodivYsio stent는 biocompatible molecule인 phosphorylcholine이 부착된 스텐트로서 관상동맥질환자에게 시술하였을 때 혈전 형성을 줄이고 재협착률을 감소시킨다고 알려져 있다. 목적 : 관상동맥 질환으로 내원하여 관상동맥 조영술을 시행한 환자 중 병변 내경이 2.0∼2.8 mm인 small vessel disease 환자를 대상으로 BiodivYsio stent와 경피적 풍선 확장술을 무작위 순서로 시행하여 BiodivYsio stent의 효용성에 대해 알아보기 위하여 본 연구를 시행하였다.대상 및 방법 : 2001년 2월부터 2001년 10월까지 전남대학교병원 순환기내과에 관상동맥 질환으로 내원하여 관상동맥 조영술을 시행한 환자 중 혈관 내경이 2.0∼2.8 mm인 small vessel disease 환자 40예를 대상으로 BiodivYsio 스텐트를 시행했던 20예의 환자군을 I군(60.8±9.3세, 남: 12, 여: 8)으로, 경피적 풍선 확장술만을 시행했던 20예의 환자군을 II군(60.3±7.9세, 남: 9, 여: 11)으로 분류하고 양군 사이에 임상적 및 관상동맥 조영술상 특성과 주요 심장사고에 대하여 전향적으로 비교하였다.결과 : 1) 임상 양상 및 검사실 소견에 있어서 양 군 사이에 유의한 차이는 없었다. 2) 병변 혈관의 수, 경색관련 혈관의 분포, ACC/AHA 형태, 혈전 내재 병변, TIMI 혈류 등 관상동맥 조영술상 양 군 간에 유의한 차이는 없었다. 3) 관상동맥 조영술상 참조 혈관 내경, 병변 최소 내경, 내경 협착률에 있어서 유의한 차이는 없었고, 양 군 모두에서 관상동맥 중재술 이후 병변 최소 내경 및 내경 협착률에 있어서 유의한 개선을 보였다. 6개월 추적 관상동맥 조영술상 II군에 비해 I군에서 병변 최소 내경의 감소 및 내경 협착률의 증가가 유의하게 적었다(1.64±0.17 mm vs 1.36±0.22 mm, 31.9±4.4% vs 43.4±9.7%, 각각 p=0.001, 0.005).

Background : The BiodivYsio stent is a balloon-expandable stent coated with phosphorylcholine designed to reduce the formation of thrombus and the risk of restenosis. Methods : We prospectively studied 20 patients who underwent implantation of BiodivYsio stent (group I; 60.8±9.3 years, male 60.0%) and compared to 20 patients who underwent balloon angioplasty alone (group II; 60.3±7.9 years, male 45.0%) for small coronary arterial lesions (target arterial diameter was between 2.0 mm and 2.8 mm) between February 2001 and October 2001. Major adverse cardiac events such as acute myocardial infarction, target vessel revascularization and death were evaluated during hospital admission and at 6-months after percutaneous coronary intervention (PCI). Results : During hospitalization, the incidence of acute myocardial infarction, target vessel revascularization and death was not different between the two groups. At follow-up coronary angiography 6 months after PCI, the incidence of restenosis was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 9/20, 45.0%, p=0.032) and the incidence of target vessel revascularization (TLR) was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 8/20, 40.0%, p=0.041). Conclusion : Coronary BiodivYsio stenting in small coronary artery leads to excellent short- and mid-term clinical outcomes.(Korean J Med 63:251-260, 2002)

Background : The BiodivYsio stent is a balloon-expandable stent coated with phosphorylcholine designed to reduce the formation of thrombus and the risk of restenosis. Methods : We prospectively studied 20 patients who underwent implantation of BiodivYsio stent (group I; 60.8±9.3 years, male 60.0%) and compared to 20 patients who underwent balloon angioplasty alone (group II; 60.3±7.9 years, male 45.0%) for small coronary arterial lesions (target arterial diameter was between 2.0 mm and 2.8 mm) between February 2001 and October 2001. Major adverse cardiac events such as acute myocardial infarction, target vessel revascularization and death were evaluated during hospital admission and at 6-months after percutaneous coronary intervention (PCI). Results : During hospitalization, the incidence of acute myocardial infarction, target vessel revascularization and death was not different between the two groups. At follow-up coronary angiography 6 months after PCI, the incidence of restenosis was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 9/20, 45.0%, p=0.032) and the incidence of target vessel revascularization (TLR) was lower in group I than in group II (Group I; 3/20, 15.0% vs Group II; 8/20, 40.0%, p=0.041). Conclusion : Coronary BiodivYsio stenting in small coronary artery leads to excellent short- and mid-term clinical outcomes.(Korean J Med 63:251-260, 2002)

Coronary artery diseases, Percutaneous coronary intervention, Restenosis, Balloon, Stents